IBOV 172,236.05 ▲ 2.22% IPC MEX 71,866.30 ▲ 0.66% MERVAL 2,848,945 — — USD/BRL5.51▲ 0.05% USD/MXN18.47▼ 0.35% USD/CLP966.96▼ 0.99% USD/COP3,267▲ 4.70% USD/PEN3.41▼ 1.07% USD/ARS1,545▼ 0.02% USD/UYU40.45▲ 0.35% USD/PYG6,450▲ 1.45% USD/BOB11.74▼ 0.59% USD/DOP60.46▼ 0.21% USD/CRC446.56▼ 0.38% USD/GTQ7.64▼ 0.05% USD/HNL26.89▲ 0.02% USD/NIO36.62▲ 2.53% USD/VES897.02▲ 0.07% USD/PAB1.00— 0.00% USD/BZD2.00— 0.00% USD/JMD157.79▲ 2.42% USD/TTD6.72▼ 0.03% EUR/BRL6.19▲ 0.99% BRENT 90.04 ▼ 2.73% WTI 84.58 ▼ 2.61% IRON ORE 161.91 — — COPPER 6.33 ▼ 0.02% GOLD 4,123 ▲ 0.21% SILVER 52.82 ▲ 0.48% SOY 1,195 ▲ 1.06% CORN 441.25 ▲ 0.46% WHEAT 591.25 ▲ 0.55% COFFEE 273.05 ▼ 2.48% SUGAR 18.15 ▼ 0.33% ORANGE JUICE 143.50 ▲ 7.85% COTTON 82.72 ▲ 5.00% COCOA 5,000 ▼ 3.01% BEEF 216.33 ▲ 1.06% CATTLE 328.83 ▲ 2.02% LITHIUM 61.35 ▲ 0.72% PETR4 45.19 ▼ 0.24% VALE3 66.11 ▲ 3.23% ITUB4 41.72 ▲ 2.94% BBDC4 14.68 ▲ 3.38% ABEV3 15.61 ▲ 0.84% BBAS3 17.02 ▼ 0.64% B3SA3 14.85 ▲ 3.20% WEGE3 50.74 ▲ 5.29% PRIO3 59.39 ▼ 1.80% SUZB3 54.20 ▲ 1.50% RENT3 30.83 ▲ 1.78% AZZA3 15.12 ▲ 2.44% CSAN3 2.77 — 0.00% RAIZ4 24.40 ▼ 12.86% PCAR3 2.43 ▲ 1.25% GMAT3 3.83 ▲ 0.79% PSSA3 45.65 ▲ 2.93% CVCB3 0.87 ▲ 3.57% POSI3 3.03 ▼ 1.94% SLCE3 17.30 ▲ 4.15% NATU3 5.71 ▲ 10.44% BRKM5 3.02 ▼ 5.63% RANI3 8.76 ▲ 3.44% CSNA3 4.49 ▲ 1.81% IBOV 172,236.05 ▲ 2.22% IPC MEX 71,866.30 ▲ 0.66% MERVAL 2,848,945 — — USD/BRL 5.51 ▲ 0.05% USD/MXN 18.45 ▼ 0.44% USD/CLP 966.96 ▼ 0.99% USD/COP 3,267 ▲ 4.70% USD/PEN 3.41 ▼ 1.07% USD/ARS 1,545 ▼ 0.02% USD/UYU 40.45 ▲ 0.35% USD/PYG 6,450 ▲ 1.45% USD/BOB 11.74 ▼ 0.59% USD/DOP 60.46 ▼ 0.21% USD/CRC 446.56 ▼ 0.38% USD/GTQ 7.64 ▼ 0.05% USD/HNL 26.89 ▲ 0.02% USD/NIO 36.62 ▲ 2.53% USD/VES 897.02 ▲ 0.07% USD/PAB 1.00 — 0.00% USD/BZD 2.00 — 0.00% USD/JMD 157.79 ▲ 2.42% USD/TTD 6.72 ▲ 2.10% EUR/BRL 6.19 ▲ 0.99% BRENT 90.04 ▼ 2.73% WTI 84.58 ▼ 2.61% IRON ORE 161.91 — — COPPER 6.33 ▼ 0.02% GOLD 4,123 ▲ 0.21% SILVER 52.82 ▲ 0.48% SOY 1,195 ▲ 1.06% CORN 441.25 ▲ 0.46% WHEAT 591.25 ▲ 0.55% COFFEE 273.05 ▼ 2.48% SUGAR 18.15 ▼ 0.33% ORANGE JUICE 143.50 ▲ 7.85% COTTON 82.72 ▲ 5.00% COCOA 5,000 ▼ 3.01% BEEF 216.33 ▲ 1.06% CATTLE 328.83 ▲ 2.02% LITHIUM 61.35 ▲ 0.72% PETR4 45.19 ▼ 0.24% VALE3 66.11 ▲ 3.23% ITUB4 41.72 ▲ 2.94% BBDC4 14.68 ▲ 3.38% ABEV3 15.61 ▲ 0.84% BBAS3 17.02 ▼ 0.64% B3SA3 14.85 ▲ 3.20% WEGE3 50.74 ▲ 5.29% PRIO3 59.39 ▼ 1.80% SUZB3 54.20 ▲ 1.50% RENT3 30.83 ▲ 1.78% AZZA3 15.12 ▲ 2.44% CSAN3 2.77 — 0.00% RAIZ4 24.40 ▼ 12.86% PCAR3 2.43 ▲ 1.25% GMAT3 3.83 ▲ 0.79% PSSA3 45.65 ▲ 2.93% CVCB3 0.87 ▲ 3.57% POSI3 3.03 ▼ 1.94% SLCE3 17.30 ▲ 4.15% NATU3 5.71 ▲ 10.44% BRKM5 3.02 ▼ 5.63% RANI3 8.76 ▲ 3.44% CSNA3 4.49 ▲ 1.81%
since 2009
Tuesday, November 10, 2026

Brazil Business - Brazil

“We are strongly entering Brazil and Mexico,” says Sorrento Therapeutics CEO

By · · 2 min read

RIO DE JANEIRO, BRAZIL – Sorrento Therapeutics, a biotech company based in San Diego (USA), which is developing an antibody treatment against Covid-19, will be stepping firmly into markets of countries like Brazil and Mexico, said the company’s CEO Henri Ji.

As certain countries are experiencing greater logistical challenges to administer vaccines, which often require very cold temperatures, opportunities are emerging for companies developing treatments and prophylactics that are easier to transport and store, he said.

“These countries need an alternative,” said Henri Ji, the company’s CEO.

Free daily brief — no card needed
Get every Brazil story in one morning email
We build you a personalized brief around the topics you follow — free for 7 days. Love it? Your first month after that is US$1.

The emergence of new and dangerous SARS-CoV-2 variants has caused concern among health officials and researchers in recent months. But tackling an evolving virus won’t necessarily be an eternal game for drug developers, notes Robbie Allen, research executive at Sorrento.

“I don’t think high-performing variants that could emerge are infinite,” he says. “The number of variants that are fit enough to compete in the overall pandemic context is lower,” he adds.

Sorrento Therapeutics headquarters in San Diego's Sorrento biotech valley.
Sorrento Therapeutics headquarters in San Diego.
RT
Ask Rio Times
Latin American markets, currencies and companies.
Open the full Ask Rio Times →

As evidence, Allen points to the convergence between amino acid changes that have occurred within the virus in several parts of the world, which suggests that evolutionary pressures are repeatedly driving the virus toward similar end points.

In October 2020, the Brazilian health regulatory agency ANVISA authorized the company to begin phase 2 trials of the antibody-based drug in Brazil, with about 400 volunteers. The drug is named “Covishield.”

According to Sorrento, these antibodies bind to the coronavirus spike protein (like a crown around the virus) and prevent the virus from entering the cell and replicating to spread the infection.

The company’s shares on NASDAQ were trading up on Tuesday, March 9th, after the announcement of an agreement with the Mount Sinai Health System to develop an antibody cocktail that can neutralize the Sars-CoV-2 virus and variants that have emerged in the UK and South Africa.

Source: Valor

This article was produced by The Rio Times’ automated AI newsroom. Editorial responsibility: Matthias Camenzind, Publisher and Editor-in-Chief. The Rio Times also runs Ask Rio Times, which answers from 100,000+ of our own articles, the daily Latin America Power Map, and prediction-market odds on elections and markets.. How we use AI · Report an error

The Rio Times · Power Map
See who really holds power in Latin America
Click to open the Power Map →

Brazil runoff date: Sunday, October 25, poll closing times and when results start · Brazil runoff polls: Flávio 51%, Lula 49% · Kalshi and Polymarket odds

Rotate for Best Experience

This report is optimized for landscape viewing. Rotate your phone for the full experience.